Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F19%3AA2001YP1" target="_blank" >RIV/61988987:17110/19:A2001YP1 - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/19:E0107808
Result on the web
<a href="https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1473574?needAccess=true" target="_blank" >https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1473574?needAccess=true</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/10428194.2018.1473574" target="_blank" >10.1080/10428194.2018.1473574</a>
Alternative languages
Result language
angličtina
Original language name
Secondary plasma cell leukemia: a multicenter retrospective study of 101 patients
Original language description
This multicenter retrospective study included 101 patients (median age 62 years) with secondary plasma cell leukemia (sPCL). The median time from initial multiple myeloma diagnosis to sPCL was 31 months. Fifty-five out of 72 patients (75%) who received any therapy were treated with immunomodulators (IMiDs) and/or proteasome inhibitors (PIs), and 14/72 (19%) underwent salvage autologous stem cell transplantation (ASCT). The overall response rate in patients who received ASCT or PI (either alone or in combination) was higher than in those who did not (93% vs. 36% and 60% vs. 30%, respectively). The median overall survival (OS) in patients who received therapy was 4.2 months (95% CI: 1.3; 8.0) with a 1-year OS of 19%. Platelet count <= 100 x 10(9)/L at sPCL diagnosis was the only independent predictor of a poorer OS in treated patients (HR = 3.98, p = .0001). These findings suggest that patients with sPCL may benefit from salvage ASCT- and PI-based regimens.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
—
Continuities
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Others
Publication year
2019
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Leukemia & Lymphoma
ISSN
1042-8194
e-ISSN
—
Volume of the periodical
60
Issue of the periodical within the volume
1
Country of publishing house
GB - UNITED KINGDOM
Number of pages
6
Pages from-to
118-123
UT code for WoS article
000458399900015
EID of the result in the Scopus database
2-s2.0-85049602239